We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-11.00 | -0.65% | 1,694.00 | 1,709.00 | 1,711.00 | 1,720.00 | 1,699.00 | 1,708.00 | 478,486 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 1,154.05 | 2.31B |
TIDMINDV
RNS Number : 1434Q
Indivior PLC
24 June 2022
Indivior Reaches Settlement with Dr. Reddy's Laboratories in Patent Infringement Case
Slough, UK and Richmond, VA, June 24, 2022 - Indivior PLC, (LON: INDV) announced that together with Aquestive Therapeutics, Inc. it entered into a settlement agreement with Dr. Reddy's Laboratories Ltd. (DRL) and its subsidiaries resolving patent litigation relating to DRL's generic buprenorphine and naloxone sublingual film, a therapeutic equivalent generic version of SUBOXONE(R) (buprenorphine and naloxone) sublingual film. The confidential settlement resolves all claims between the parties and the amount paid by Indivior to DRL pursuant to the settlement is consistent with its previously disclosed reserve amount.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on
LinkedIn by visiting www.linkedin.com/company/indivior .
For Further Information
Jason Thompson VP, Investor +1 804 402 7123 Relations jason.thompson@indivior.com Indivior PLC Tim Owens Director, Investor +1 804 263 3978 Relations Indivior timothy.owens@indivior.com PLC
-ends-
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
UPDBKQBQKBKDNAB
(END) Dow Jones Newswires
June 24, 2022 06:45 ET (10:45 GMT)
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions